Its principal constituent is a mucopolysacccharide comBackground. Low-molecular-weight heparin (LMWH ) prising -glucuronic acid and -glucosamine, both has been suggested as providing safe, efficient, conveni-sulphated, in 1,4-a linkage, with a spread of molecular ent and possibly more cost-effective anticoagulation weights of between 6000 and 30 000 daltons (mean for haemodialysis (HD) than unfractionated heparin, 15 000). Although standard systemic heparinization for with fewer side-effects and possible benefits on uraemic haemodialysis is relatively safe and effective, long-term dyslipidaemia.
Introduction
Subjects and methods into the study ( Table 1) . Informed consent was obtained Clinical monitoring from all participants. Patients received haemodialysis thrice weekly for 3-5 h per session at blood flow rates of In order to assess the efficacy of anticoagulation, the fre-250-320 ml/min, mainly with cellulosic hollow-fibre mem-quency and degree of fibrin/clot formation in both the brane dialysers. Vascular access was via a native arterio-dialyser and lines were graded on a 10-point scale, with 1 venous fistula or an artificial graft. Patients with known indicating no clot formation and 10 very heavy clotting or bleeding disorders were excluded. Subjects receiving oral or total occlusion (100%). This assessment was carried out after other forms of anticoagulant therapy (e.g. warfarin, aspirin) the blood had been returned to the patient by flushing the or drugs that could affect heparin activity (e.g. tetracyclines, dialyser and lines with normal saline. Episodes of adverse digitalis, and antihistamines) were also excluded. Subjects events such as haemorrhage or thrombosis either during or continued their usual medication (including lipid-lowering between dialyses were also noted. Haemorrhages were cattherapy in some) and were treated in the normal manner by egorized as slight/minor, moderate, or severe. The Clexane their caring physicians during the study. Human recombinant dose was reduced by 0.2 mg/kg if indicated by excess bleeding erythropoietin was given where necessary to maintain a from needle puncture sites during or between dialyses. target haemoglobin of 11-12 g/100 ml. Post-HD haemostasis was assessed by recording vascular Eligible subjects were randomly assigned to receive either access compression times with a stopwatch, observing the enoxaparin sodium (Clexane; 1 mg/kg body weight) or con-time from needle removal to cessation of spontaneous bleedtinue standard sodium heparin and followed prospectively ing/oozing from the puncture site. for 12 weeks (36 dialyses). Subjects were then crossed over to the alternate therapy and followed for a further 12 weeks Laboratory estimations (36 dialyses).
Heparin (sodium heparin 5000 IU/ml ) was administered Fasting standard lipid profiles were determined pre-dialysis as a bolus dose (50 IU/kg body weight) intravenously into at baseline (week 0) and at the end of each arm of the study. the pre-dialyser arterial line of the extracorporeal blood Total cholesterol (TC ), high-density lipoprotein cholesterol circuit, followed by a maintenance dose of 1000 IU sodium (HDL), and triglyceride concentrations (Trigs) were measheparin per hour. Infusion was discontinued 1 h prior to ured on a high-throughput autoanalyser (Hitachi 747) using cessation of HD. Activated coagulation times were monitored reagents supplied by Boehringer Mannheim (Germany). hourly using an Actester (Trimed) to maintain times around Low-density lipoprotein cholesterol (LDL) and very-200 s early in the HD session and 150 s later in the session.
low-density lipoprotein cholesterol ( VLDL) were calculated LMW heparin (Clexane; 100 mg/ml ampoules) was admin-using The significance of differences between groups was deterThe cost per treatment was calculated for each therapy by mined using analysis of variance (ANOVA) for parametric including the cost of the drug and disposable items. The data or Kruskal-Wallis ANOVA on ranks for noncalculations thus included the average cost of dialyser, blood parametric data as appropriate. Paired data was compared lines, heparin syringes, and normal saline priming solutions using the paired t-test. Non-parametric data was compared but excluded nursing time. Costs of disposable items using Mann-Whitney rank sum test. The significance of (Actester tubes, syringes, and needles) for activated coagula-proportions was assessed by the z-test. A probability P<0.05 tion times were included in cost per treatment using heparin. was considered significant. Data are expressed as means±SD Although additional nursing intervention was required to except where otherwise indicated. check sodium heparin administration and to carry out activated coagulation times, these tasks were generally carried out during normal/usual patient contact time. The cost of Results adverse events included the cost of syringes, drugs (e.g. protamine), surgical applications (swabs, calcium alginate The study was designed as a prospective, randomized, fibre, pressure plasters), replacement dialysers and lines, and cross-over study, with patients randomly assigned to cost of hospitalization if applicable. The latter was based on receive either unfractionated heparin or Clexane as the the standard daily cost of a hospital bed in our facility. The first mode of treatment. However, as no difference was study protocol was approved by the Human Ethics noted between the two sections of the study for any Committee of the Royal Brisbane Hospital.
of the parameters measured, data for each phase was pooled. Five subjects did not finish the study: three and the dose reduced in those affected patients. The mean dose in our patients at the end of the study was 0.69±0.25 mg/kg body weight (range 0.29-1.25 mg/kg; Figure 3 ). One patient experienced significant extracorporeal clotting, and eventually required a dose of 1.25 mg/kg. Ninety per cent of patients were anticoagulated with 0.34-1.08 mg/kg. After Clexane dose reduction, the frequency of minor haemorrhagic events decreased by 44% (from 7.7 to 4.3%, Table 2 ) eliminating the difference between the two groups (P=0.087). The frequency of minor clotting (grades 2-4) was unchanged, but the frequency of clear dia- anticoagulation (P<0.001). The appearance of significant clots (grades 4-10) in both lines and dialysers was infrequent, with no difference using either type of heparin. Clexane use was accompanied by a significantly higher frequency of minor haemorrhage between dialyses (7.7 vs 2.8%; P<0.001) ( Table 2) . During the 
014). Discussion
Interestingly, the frequency of moderate occlusion (grade 4) and severe occlusion (grades 8-10) of the While the benefits of LMW heparin over standard, dialysers actually fell after dose titration (P<0.05).
unfractionated heparin in the treatment and prophy-A measure of haemostasis at the puncture sites was laxis of venous thromboembolism are well established, obtained by recording vascular access clotting times at the relative merits of LMW heparin for haemodialysis the end of haemodialysis with a stop-watch. There was coagulation are less clear. The ease of administration no significant difference in clotting times for either of LMW heparin (single bolus pre-dialysis) and lack anticoagulation modality ( Table 3) . Three patients of laboratory monitoring would seem clear advantages. received packed-cell transfusions while on Clexane However, early in the course of the Clexane arm of compared to two during the heparin arm. Intravenous the study, we observed an increased frequency of minor iron (iron polymaltose complex (Ferrum H, Sigma interdialytic haemorrhage (none requiring clinical Pharmaceuticals Pty Ltd, Victoria, Australia) equiva-intervention). This problem may not become apparent lent to 600 mg elemental iron) was given according until after several (4-8) dialyses. Moderate and severe to our unit's protocol (serum ferritin <200 mg/l± haemorrhagic events, however, were rare in both heptransferrin saturation <20% on routine monthly tests), arin groups; moreover, there was no difference in the 10 times in the Clexane and eight times in the heparin frequency of haemorrhage or thrombosis between the phase of the study.
groups. If the initial phase of minor bleeding between To determine whether the type of anticoagulation dialyses is discounted, our observations are in line with had any effect on dialyser uraemic solute clearance, earlier studies comparing Fragmin [19] , Braun 21-23 Kt/Vurea values were obtained using the Theraps [20] , and Fraxiparin [21] with unfractionated heparin. management system (Cobe, Colorado, USA). Data
While the study was not specifically a dose-finding was available for 20 patients. There was no difference study, we began with the manufacturer's recommended between the groups (1.45±0.16 for Clexane vs dose for Clexane. The bleeding tendency between dia-1.46±0.13 for heparin; P=0.790).
lyses led to a re-examination of patients' doses, and No changes in serum lipids were observed with either downward dose adjustment in several patients. Two anticoagulant ( Table 4) .
earlier studies have similarly used lower doses than The cost per treatment was slightly higher with recommended by the manufacturer. A French mulClexane: $37.26 Australian dollars ( US$ 24.22) vs ticentre, dose-finding study involving 72 patients found $31.55 ( US$ 20.51) with sodium heparin. The median that nearly half the patients (41%) were adequately cost of adverse events arising from Clexane anticoagul-anticoagulated with enoxaparin 0.5 mg/kg, the remaination was slightly higher than with heparin (1.39 cents der requiring 0.6-0.9 mg/kg (mean 0.62±0.16 mg/kg) vs 0.44 cents Aus per patient per dialysis). This differ- [22] . In an extended trial involving 115 consecutive ence, which was not statistically significant (P=0.081), haemodialyses in 35 HD patients, other researchers was reduced if the period after dose titration only was used enoxaparin 0.88 mg/kg body weight (range considered (0.64 cents vs 0.44 cents; P=0.598).
0.33-1.0 mg/kg) [23] . In our view, the recommended dose of 1 mg Clexane/kg BW for haemodialysis is too and heparin. This suggested that blood flow through the dialysers, and hence solute clearances, were not average cost per treatment has effectively decreased from $37.26 Australian ( US$ 24.22) to $35.25 significantly affected by the choice of anticoagulant.
In addition to its anticoagulation properties, unfrac-Australian ( US$ 22.91). This is approximately 10.5% higher than the cost of heparin anticoagulation. tionated heparin is known to release lipoprotein lipase from its active site at the capillary endothelial surface.
